Key result
Among patients with young-onset hypertension, the prevalence of primary aldosteronism was 17.8%, increasing with hypertension grade, number of medications, and severity of hypokalaemia.
Why the study?
Despite being the most common cause of secondary hypertension, the prevalence of primary aldosteronism among patients with young-onset hypertension remains poorly studied.
Cross-Sectional (n=202)
No
There is a high prevalence (17.8%) and long delay in diagnosis of primary aldosteronism among patients with young-onset hypertension, suggesting this group should be considered high-risk in screening algorithms.
May warrant targeted PA screening in young-onset hypertension; leaves open optimal thresholds and outcome impact.
BACKGROUND: Despite being the most common cause of secondary hypertension, prevalence of primary aldosteronism (PA) among patients with young-onset hypertension (YH - age of hypertension onset <40 years) remains poorly studied. OBJECTIVE: We assessed the prevalence of PA in patients with YH referred for evaluation of secondary hypertension. DESIGN AND PATIENTS: In this prospective, cross-sectional study, 202 patients with YH, visiting endocrine and cardiology clinics of All India Institute of Medical Sciences, India, were evaluated. MEASUREMENTS: Primary aldosteronism was screened by measuring plasma aldosterone concentration (PAC) and direct renin concentration (DRC) and calculating aldosterone-to-renin ratio (ARR), followed by confirmatory saline infusion test (SIT) according to Endocrine Society Guideline. Those confirmed with post-SIT PAC >5 ng/dl underwent adrenal computed tomography (CT), followed by adrenal venous sampling (AVS). RESULTS: Of 202 YH patients, 38 (18.8%) screened positive, and PA was confirmed in 36 (17.8%). The mean age was 43.9 ± 10.9 years, and median duration of hypertension was 10.5 (3.5-18) years. The prevalence of PA increased with grade of hypertension (8.1% in grade 1 to 37.1% in grade 3), number of antihypertensive medications (2.5% in those taking ≤1 to 50% in those taking ≥4 medications) and severity of hypokalaemia (0% in potassium >5 to 85.7% in potassium <3.5 mmol/L). The prevalence of PA by age of hypertension onset was highest in age group 30-39 years (31.3%). CONCLUSIONS: There is a high prevalence and a long delay in diagnosis of PA among patients with YH, and YH should be considered as a separate high-risk category in PA screening algorithm.
No takes yet. Share an insight, caveat, or question.
Alam et al. (2021) conducted a cross-sectional in Young-onset hypertension (n=202). Young-onset hypertension was evaluated on Prevalence of primary aldosteronism. Among patients with young-onset hypertension, the prevalence of primary aldosteronism was 17.8%, increasing with hypertension grade, number of medications, and severity of hypokalaemia.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: